Back to results
US 2023/0416404 A1Published application
Factor x binders enhancing fx activation
AssigneeNovo Nordisk A/S
InventorsJacob Lund, Karina Thorn, Mikkel Nors Harndahl, Marie-Ange Buyse, Evelyn De Tavernier, Soren Steffensen
Life of this patent
Estimating the term…
Abstract
The application relates to unique FX binding molecules, such as antibodies and fragments thereof which are useful in the treatment of haemophilia.
Claims12
A nanobody capable of binding FX, wherein the nanobody is capable of making FX more prone to proteolysis by FIXa and wherein the nanobody is capable of binding the activation peptide of FX (amino acid residues 143-194 of SEQ ID NO:2),
- wherein the common minimal epitope, as determined by peptide array, comprises amino acid residues “LL” (amino acid residues 177-178 of SEQ ID NO:2), and
- wherein the nanobody is at least 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to the sequence identified by SEQ ID NO:10.
A nanobody capable of binding FX
- a. comprising SEQ ID NO:10, or
- b. comprising three CDR sequences, wherein the three CDR sequences have at most amino acid changes compared to those of SEQ ID NO:10,
- wherein the antibody or antigen-binding fragment thereof is capable of making FX more prone to proteolysis by FIXa.
Dependencies are inferred from the claim text.